Omnichannel Group Transformation

A global top-10 pharma company needed to scale its Omnichannel group while deepening integration with other internal teams. The COVID-19 pandemic and a 25% increase in OpEx reduction targets created additional urgency.

• Launched employee-driven innovation task forces to shape new capabilities.
• Established a brand-funded investment model to support scaling.
• Mobilized a COVID-19 cross-franchise response, reducing MLR submission sizes by ~50% for dynamic content.
• Expanded partnerships to include Medical Affairs Omnichannel collaboration.

• Scaled team capacity from ~15 people to ~70 over two years.
• Accelerated dynamic content approvals.
• Helped double the number of franchises adopting the model.